Things appear good right now The board should see a quarter or two of results before taking action to split the stock. The Affymax tragedy makes Amgen products the treatment that will be used for some time. The rate at which new treatments are released and adopted is where real value in this company is. The top level executives and the board have a lot more insight into these matters than the shareholders. A split would be nice, but only if the company can increase earnings in the future because it is providing more of the wonder treatments that brought it to this point.